1
|
Damm-Welk C, Luedersen J, Stadt U, Richter J, Oschlies I, Klapper W, Rosenwald A, Kalinova M, Simonitsch-Klupp I, Siebert R, Zimmermann M, Alawi M, Nakel J, Scheinemann K, Knörr F, Attarbaschi A, Kabickova E, Woessmann W. VARIANT ALK-FUSION POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA (ALCL): A POPULATION-BASED COHORT OF THE NHL-BFM STUDY GROUP. Leuk Res 2022. [DOI: 10.1016/s0145-2126(22)00235-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
2
|
Griss JG, Drach M, Thaler F, Shaw L, Mann U, Wagner C, Wagner S, Weninger W, Simonitsch-Klupp I, Farlik M, Jonak C, Brunner PM. Single-cell RNA sequencing analyses of primary cutaneous B-cell disorders reveal distinct molecular patterns consistent with clinical behavior. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00555-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
3
|
Jeryczynski G, Antlanger M, Duca F, Binder-Rodriguez C, Reiter T, Simonitsch-Klupp I, Bonderman D, Kain R, Krauth MT, Agis H. First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience. ESMO Open 2021; 6:100065. [PMID: 33667762 PMCID: PMC7937667 DOI: 10.1016/j.esmoop.2021.100065] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2020] [Revised: 01/08/2021] [Accepted: 01/24/2021] [Indexed: 11/25/2022] Open
Abstract
Background Daratumumab was the first monoclonal CD38 antibody with single-agent activity approved for the treatment of multiple myeloma. Moreover, daratumumab demonstrated high response rates in relapsed immunoglobulin light-chain (AL) amyloidosis. Patients and methods In our single-center retrospective real-life case series, we analyzed the efficacy and safety of daratumumab as first-line treatment. Daratumumab was administered with low-dose dexamethasone alone or in combination with other multiple myeloma therapeutics Results Fourteen patients were eligible, including nine patients with cardiac stage IIIa or IIIb. Overall hematologic response rate was 100%, with 64.3% achieving complete response after a median of 16 cycles of treatment. Median time to hematologic response was 1.4 months. Organ response rates were 45.5% after a median of 4.0 months and 66.7% after a median of 10.0 months, for heart and kidney involvement, respectively. After a median follow-up of 20.5 months, two patients underwent successful autologous stem cell transplantation (ASCT), while another three patients were in preparation for ASCT. Three patients remained on daratumumab at the last follow-up. There were no unexpected toxicities and no grade III or IV adverse events, although more than half of our patients were in stage IIIa or IIIb. Conclusion Daratumumab proved to be highly effective in newly diagnosed AL amyloidosis with excellent hematologic and organ response rates, a remarkable safety profile, and good tolerability even in patients with advanced stage of disease. Daratumumab yields high hematologic response rates in untreated AL amyloidosis. Treatment is well tolerated even in advanced disease stages. No unexpected toxicity was observed.
Collapse
Affiliation(s)
- G Jeryczynski
- Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
| | - M Antlanger
- Department of Internal Medicine 2, Kepler University Hospital, Johannes Kepler University Linz, Linz, Austria
| | - F Duca
- Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
| | - C Binder-Rodriguez
- Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
| | - T Reiter
- Division of Nephrology and Dialysis, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
| | | | - D Bonderman
- Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
| | - R Kain
- Department of Pathology, Medical University of Vienna, Vienna, Austria
| | - M-T Krauth
- Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
| | - H Agis
- Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria; Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
| |
Collapse
|
4
|
Greiner G, Gurbisz M, Ratzinger F, Witzeneder N, Class S, Simonitsch-Klupp I, Esterbauer H, Mayerhofer M, Müllauer L, Sperr W, Valent P, Hoermann G. KIT D816V tissue mutation burden is a new biomarker and independent predictor of survival in mastocytosis. Clin Chim Acta 2019. [DOI: 10.1016/j.cca.2019.03.1222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
5
|
Raderer M, Dolak W, Simonitsch-Klupp I, Kiesewetter B. DEPTH OF REMISSION FOLLOWING FIRST LINE HP-ERADICATION IS AN INDEPENDENT PROGNOSTIC FACTOR IN GASTRIC MALT LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.71_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M. Raderer
- Internal Medicine I; Oncology, Medical University Vienna; Vienna Austria
| | - W. Dolak
- Gastroenterology; Medical University Vienna; Vienna Austria
| | | | - B. Kiesewetter
- Internal Medicine I; Oncology, Medical University Vienna; Vienna Austria
| |
Collapse
|
6
|
Kiesewetter B, Lamm W, Dolak W, Lukas J, Mayerhoefer M, Weber M, Kornauth C, Schiefer A, Bayer G, Simonitsch-Klupp I, Raderer M. TRANSFORMED MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMAS: A SINGLE INSTITUTION RETROSPECTIVE STUDY INCLUDING PCR-BASED CLONALITY ANALYSIS. Hematol Oncol 2019. [DOI: 10.1002/hon.73_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- B. Kiesewetter
- Department of Medicine I; Clinical Division of Oncology, Medical University of Vienna; Vienna Austria
| | - W. Lamm
- Department of Medicine I; Clinical Division of Oncology, Medical University of Vienna; Vienna Austria
| | - W. Dolak
- Department of Medicine III; Clinical Division of Gastroenterology and Hepatology, Medical University of Vienna; Vienna Austria
| | - J. Lukas
- Department of Ophthalmology and Optometry; Medical University of Vienna; Vienna Austria
| | - M.E. Mayerhoefer
- Department of Biomedical Imaging and Image-guided Therapy; Division of Nuclear Medicine, Medical University of Vienna; Vienna Austria
| | - M. Weber
- Department of Biomedical Imaging and Image-guided Therapy; Division of Nuclear Medicine, Medical University of Vienna; Vienna Austria
| | - C. Kornauth
- Department of Pathology; Medical University of Vienna; Vienna Austria
| | - A.I. Schiefer
- Department of Pathology; Medical University of Vienna; Vienna Austria
| | - G. Bayer
- Department of Pathology; Medical University of Vienna; Vienna Austria
| | | | - M. Raderer
- Department of Medicine I; Clinical Division of Oncology, Medical University of Vienna; Vienna Austria
| |
Collapse
|
7
|
Kiesewetter B, Lamm W, Mayerhoefer M, Dolak W, Lukas J, Simonitsch-Klupp I, Raderer M. FIRST LINE SYSTEMIC TREATMENT IN MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT) LYMPHOMA NOT ELIGIBLE FOR H. PYLORI ERADICATION - DO WE NEED CHEMOTHERAPY? Hematol Oncol 2019. [DOI: 10.1002/hon.125_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- B. Kiesewetter
- Department of Medicine I; Clinical Division of Oncology, Medical University of Vienna; Vienna Austria
| | - W. Lamm
- Department of Medicine I; Clinical Division of Oncology, Medical University of Vienna; Vienna Austria
| | - M.E. Mayerhoefer
- Department of Biomedical Imaging and Image-guided Therapy; Division of Nuclear Medicine, Medical University of Vienna; Vienna Austria
| | - W. Dolak
- Department of Medicine III; Clinical Division of Gastroenterology and Hepatology, Medical University of Vienna; Vienna Austria
| | - J. Lukas
- Department of Ophthalmology and Optometry; Medical University of Vienna; Vienna Austria
| | | | - M. Raderer
- Department of Medicine I; Clinical Division of Oncology, Medical University of Vienna; Vienna Austria
| |
Collapse
|
8
|
Bauer WM, Aichelburg MC, Griss J, Skrabs C, Simonitsch-Klupp I, Schiefer AI, Kittler H, Jäger U, Zeyda M, Knobler R, Stingl G. Molecular classification of tumour cells in a patient with intravascular large B-cell lymphoma. Br J Dermatol 2017; 178:215-221. [PMID: 28733977 DOI: 10.1111/bjd.15841] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/11/2017] [Indexed: 11/28/2022]
Abstract
BACKGROUND Intravascular large B-cell lymphoma (IVLBCL) is a rare type of extranodal LBCL. It is characterized by the proliferation of tumour cells exclusively intraluminally in small blood vessels of different organs. The clinical manifestation depends on the type of organ affected; additionally, a haemophagocytic syndrome can be observed in some patients. OBJECTIVES The aim was to further understand the nosology of this lymphoma as, due to its rarity and in spite of detailed immunohistochemical investigations, its exact nosology is only incompletely understood. METHODS We used microarray-based analysis of gene expression of tumour cells isolated from a patient with primary manifestation of the lymphoma in the skin and compared it with various other diffuse LBCLs (DLBCLs) as well as a previously published DLBCL classifier. RESULTS In unsupervised analyses, the tumour cells clustered together with non-germinal centre B-cell (non-GCB) DLBCL samples but were clearly distinct from GCB-DLBCL. Analogous to non-GCB DLBCL, molecular cell-of-origin classification revealed similarity to bone-marrow derived plasma cells. CONCLUSIONS The IVLBCL of this patient showed molecular similarity to non-GCB DLBCL. Due to the prognostic and increasingly also therapeutic relevance of molecular subtyping in DLBCL, this method, in addition to immunohistochemistry, should also be considered for the diagnosis of IVLBCL in the future.
Collapse
Affiliation(s)
- W M Bauer
- Department for Dermatology, Division of Immunology, Allergy and Infectious Diseases, Medical University of Vienna, Vienna, Austria
| | - M C Aichelburg
- Department for Dermatology, Division of Immunology, Allergy and Infectious Diseases, Medical University of Vienna, Vienna, Austria
| | - J Griss
- Department for Dermatology, Division of Immunology, Allergy and Infectious Diseases, Medical University of Vienna, Vienna, Austria
| | - C Skrabs
- Department of Internal Medicine I, Division of Haematology and Haemostaseology, Medical University of Vienna, Vienna, Austria
| | | | - A I Schiefer
- Department for Pathology, Medical University of Vienna, Vienna, Austria
| | - H Kittler
- Department for Dermatology, Division of General Dermatology, Medical University of Vienna, Vienna, Austria
| | - U Jäger
- Department of Internal Medicine I, Division of Haematology and Haemostaseology, Medical University of Vienna, Vienna, Austria
| | - M Zeyda
- Division of Endocrinology and Metabolism, Department of Medicine III, Medical University, of Vienna, Vienna, Austria
| | - R Knobler
- Department for Dermatology, Division of General Dermatology, Medical University of Vienna, Vienna, Austria
| | - G Stingl
- Department for Dermatology, Division of Immunology, Allergy and Infectious Diseases, Medical University of Vienna, Vienna, Austria
| |
Collapse
|
9
|
Kiesewetter B, Mayerhoefer M, Dolak W, Lukas J, Simonitsch-Klupp I, Raderer M. PROGRESSION-FREE SURVIVAL FOLLOWING LENALIDOMIDE-BASED TREATMENT IS SIGNIFICANTLY LONGER IN EXTRAGASTRIC THAN IN GASTRIC MARGINAL ZONE B-CELL LYMPHOMA OF THE MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA (MALT LYMPHOMA). Hematol Oncol 2017. [DOI: 10.1002/hon.2438_77] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- B. Kiesewetter
- Medicine I, Clin. Div. of Oncology; Medical University Vienna; Vienna Austria
| | | | - W. Dolak
- Medicine III, Clin. Division of Gastroenterology and Hepatology; Medical University Vienna; Vienna Austria
| | - J. Lukas
- Ophthalmology; Medical University Vienna; Vienna Austria
| | | | - M. Raderer
- Medicine I, Clin. Div. of Oncology; Medical University Vienna; Vienna Austria
| |
Collapse
|
10
|
Gisslinger H, Jeryczynski G, Gisslinger B, Wölfler A, Burgstaller S, Buxhofer-Ausch V, Schalling M, Krauth MT, Schiefer AI, Kornauth C, Simonitsch-Klupp I, Beham-Schmid C, Müllauer L, Thiele J. Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria. Leukemia 2017; 31:774-775. [PMID: 28248312 PMCID: PMC7608183 DOI: 10.1038/leu.2016.291] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
11
|
Kiesewetter B, Mayerhoefer M, Dolak W, Simonitsch-Klupp I, Lukas J, Raderer M. 3227 A phase II trial of ofatumumab for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma) - An interim analysis. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31804-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
12
|
Oschlies I, Simonitsch-Klupp I, Maldyk J, Konovalov D, Abramov D, Myakova N, Lisfeld J, Attarbaschi A, Kontny U, Woessmann W, Klapper W. Subcutaneous panniculitis-like T-cell lymphoma in children: a detailed clinicopathological description of 11 multifocal cases with a high frequency of haemophagocytic syndrome. Br J Dermatol 2015; 172:793-7. [PMID: 25456748 DOI: 10.1111/bjd.13440] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Affiliation(s)
- I Oschlies
- Department of Pathology, Hematopathology Section and Lymph Node Registry, Christian-Albrecht University Kiel and University Hospital Schleswig-Holstein, Campus Kiel, Michaelisstr. 11, 24105, Kiel, Germany.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Agis H, Krauth MT, Mosberger I, Müllauer L, Simonitsch-Klupp I, Schwartz LB, Printz D, Böhm A, Fritsch G, Horny HP, Valent P. Enumeration and immunohistochemical characterisation of bone marrow basophils in myeloproliferative disorders using the basophil specific monoclonal antibody 2D7. J Clin Pathol 2006; 59:396-402. [PMID: 16461568 PMCID: PMC1860377 DOI: 10.1136/jcp.2005.029215] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND Basophils are highly specialised granulocytes that express a unique profile of antigens and increase in myeloproliferative disorders (MPD). In chronic myeloid leukaemia (CML), basophilia is a diagnostic and prognostic determinant. So far, however, no reliable approach for routine detection and enumeration of bone marrow basophils has become available. OBJECTIVE To detect and enumerate basophils in bone marrow sections in patients with CML and other MPD. METHODS The anti-basophil antibody 2D7 was applied to paraffin embedded bone marrow sections from normal/reactive subjects (n = 31), patients with CML (chronic phase, n = 37; accelerated phase, n = 9), and other MPD (chronic idiopathic myelofibrosis (CIMF), n = 20; polycythaemia vera (PV), n = 20; essential thrombocythaemia (ET), n = 20; indolent systemic mastocytosis (ISM), n = 7). RESULTS As assessed by serial section staining, 2D7(+) cells were found to co-express myeloperoxidase, histidine decarboxylase, CD9, and CD43, but did not express B cell or T cell restricted antigens. 2D7(+) bone marrow cells were found to increase in CML compared with normal/reactive bone marrow and other MPD (median numbers of 2D7(+) cells/mm(2): CML, 33; normal/reactive bone marrow, 6; CIMF, 10; PV, 6; ET, 5; ISM, 3; p<0.05). The highest basophil counts were recorded in accelerated phase CML (115/mm(2)). CONCLUSIONS A novel immunohistochemical procedure has been established for basophil detection in normal bone marrow and MPD. This approach should help in the quantification of bone marrow basophils at diagnosis and during anti-leukaemic treatment.
Collapse
Affiliation(s)
- H Agis
- Department of Internal Medicine I, Division of Haematology and Haemostaseology, Medical University of Vienna, Austria
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Schützinger C, Gaiger A, Thalhammer R, Vesely M, Fritsche-Polanz R, Schwarzinger I, Ohler L, Simonitsch-Klupp I, Reinhard F, Jäger U. Remission of pure red cell aplasia in T-cell receptor γδ-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab. Leukemia 2005; 19:2005-8. [PMID: 16193089 DOI: 10.1038/sj.leu.2403956] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
MESH Headings
- Aged
- Aged, 80 and over
- Alemtuzumab
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Humanized
- Antibodies, Neoplasm/therapeutic use
- Antineoplastic Agents/therapeutic use
- Genes, T-Cell Receptor delta
- Genes, T-Cell Receptor gamma
- Humans
- Leukemia, T-Cell/complications
- Male
- Red-Cell Aplasia, Pure/drug therapy
- Red-Cell Aplasia, Pure/etiology
Collapse
|
15
|
Streubel B, Simonitsch-Klupp I, Müllauer L, Lamprecht A, Huber D, Siebert R, Stolte M, Trautinger F, Lukas J, Püspök A, Formanek M, Assanasen T, Müller-Hermelink HK, Cerroni L, Raderer M, Chott A. Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia 2004; 18:1722-6. [PMID: 15356642 DOI: 10.1038/sj.leu.2403501] [Citation(s) in RCA: 260] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Although several recurrent genetic aberrations are known to occur in MALT lymphoma, no comprehensive study on the most prevalent MALT lymphoma-associated genetic aberrations is available. We therefore screened 252 primary MALT lymphomas for translocations t(11;18)(q21;q21), t(14;18)(q32;q21), and t(1;14)(p22;q32), and trisomies 3 and 18. The above-listed translocations occurred mutually exclusively and were detected overall in 13.5, 10.8, and 1.6% of the cases; trisomy 3 and/or 18 occurred in 42.1%. The frequency at which the translocations occurred varied markedly with the primary site of disease. The t(11;18)(q21;q21) was mainly detected in pulmonary and gastric tumors, whereas the t(14;18)(q32;q21) was most commonly found in lesions of the ocular adnexa/orbit, skin, and salivary glands. Trisomies 3 and 18 each occurred most frequently in intestinal and salivary gland MALT lymphomas. Our results demonstrate that the three translocations and trisomies 3 and 18 occur at markedly variable frequencies in MALT lymphoma of different sites.
Collapse
MESH Headings
- Chromosome Aberrations
- Chromosomes, Human, Pair 11/genetics
- Chromosomes, Human, Pair 14/genetics
- Chromosomes, Human, Pair 18/genetics
- Chromosomes, Human, Pair 3/genetics
- Gene Frequency
- Genetic Variation
- Humans
- In Situ Hybridization, Fluorescence
- Lymphoma, B-Cell, Marginal Zone/classification
- Lymphoma, B-Cell, Marginal Zone/genetics
- Lymphoma, B-Cell, Marginal Zone/pathology
- Organ Specificity
- Translocation, Genetic
- Trisomy/genetics
Collapse
Affiliation(s)
- B Streubel
- Institute of Pathology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Mitterbauer-Hohendanner G, Mannhalter C, Winkler K, Mitterbauer M, Skrabs C, Chott A, Simonitsch-Klupp I, Gleiss A, Lechner K, Jaeger U. Prognostic significance of molecular staging by PCR-amplification of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma (DLBCL). Leukemia 2004; 18:1102-7. [PMID: 15085149 DOI: 10.1038/sj.leu.2403376] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The prognostic value of the detection of peripheral blood (PB) and/or bone marrow (BM) involvement by polymerase chain reaction (PCR) amplification of rearranged immunoglobulin heavy chain (IgH) and immunoglobulin kappa light chain (Igkappa) genes was evaluated in 155 patients with diffuse large B-cell lymphomas (DLBCL). Immunoglobulin gene rearrangements (IgR) were detected in 35/155 (23%) patients. The presence of IgR in PB/BM was related to clinical stage (CS I-III vs CS IV; P<0.001), histopathological detection of BM involvement (P<0.001), and the International Prognostic Index (P<0.001). IgR-positive cases had a significantly lower complete remission (CR) rate (18/35, 51%) than IgR-negative patients (85/120, 71%; P=0.042), and a significantly poorer overall survival (OAS) at 5 years (25 vs 66%; P<0.001). There was a significant difference in the estimated OAS at 5 years between patients with negative BM histology and negative PCR results (66%), patients with negative BM histology but positive IgR (37%), and patients with positive BM histology (12%). Our results indicate that molecular methods improve the accuracy of staging in patients with DLBCL and define a group of patients with normal bone marrow histology who have a significantly poorer OAS due to molecular detection of PB/BM involvement.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Biopsy
- Bone Marrow/pathology
- Clone Cells
- DNA, Neoplasm/analysis
- Gene Rearrangement, B-Lymphocyte
- Humans
- Lymphoma, B-Cell/genetics
- Lymphoma, B-Cell/mortality
- Lymphoma, B-Cell/pathology
- Lymphoma, Large B-Cell, Diffuse/genetics
- Lymphoma, Large B-Cell, Diffuse/mortality
- Lymphoma, Large B-Cell, Diffuse/pathology
- Middle Aged
- Neoplasm Staging/methods
- Polymerase Chain Reaction
- Prognosis
- Survival Analysis
Collapse
Affiliation(s)
- G Mitterbauer-Hohendanner
- Clinical Institute of Medical and Chemical Laboratory Diagnostics, Division of Molecular Diagnostics, University of Vienna, Medical School, Währinger Gürtel, Vienna, Austria
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Simonitsch-Klupp I, Hauser I, Ott G, Drach J, Ackermann J, Kaufmann J, Weltermann A, Greinix HT, Skrabs C, Dittrich C, Lutz D, Pötter R, Mannhalter C, Lechner K, Chott A, Jaeger U. Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome. Leukemia 2004; 18:146-55. [PMID: 14603341 DOI: 10.1038/sj.leu.2403206] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
To define reproducible criteria for subgroups of diffuse large B-cell lymphomas (DLBCL), including lymphomas with plasmablastic/plasmacytoid features (PB/PC-Fs), we investigated 66 DLBCL; the samples were categorized as either centroblastic (CB), immunoblastic (IB) or PB/PC-F applying standardized morphologic criteria. Blinded specimens were reviewed by three independent pathologists. The final consensus classification included 44 CB (67%), seven IB (10%) and 15 PB/PC-F (23%). The interobserver agreement between two centers (Vienna, Würzburg) was 93.5%. Most PB/PC-F were CD20+, cIgM+, MUM-1+, CD138+/-, bcl-6-, corresponding to an activated B-cell phenotype. Immunoglobulin-V(H) gene mutation analysis was consistent with a germinal or postgerminal center-cell origin. By fluorescence in situ hybridization analysis, 11/13 (85%) PB/PC-F had a monoallelic TP53 deletion. The pretreatment characteristics of patients with PB/PC-F included a tendency for more B symptoms, extranodal disease and a higher IPI. Importantly, PB/PC-F were resistant to standard chemotherapy (complete remission rate 47%, relapse rate 71%) and even autologous stem-cell transplantation. The median overall survival (OS) (14 months, P<0.002) and disease-free survival (6 months, P=0.02) were significantly shorter compared to patients with CB and IB. The OS difference was pronounced within the low and low-intermediate IPI risk group (P<0.001). Our data indicate a strong association of plasmablastic/plasmacytoid morphology with TP53 deletions, poor response to chemotherapy and short survival.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Antigens, Neoplasm/analysis
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Biomarkers/analysis
- Female
- Follow-Up Studies
- Genes, Immunoglobulin
- Genes, p53/genetics
- Germinal Center/immunology
- Herpesvirus 4, Human/genetics
- Humans
- Immunophenotyping
- In Situ Hybridization, Fluorescence
- Lymphoma, B-Cell/classification
- Lymphoma, B-Cell/mortality
- Lymphoma, B-Cell/pathology
- Lymphoma, Large B-Cell, Diffuse/classification
- Lymphoma, Large B-Cell, Diffuse/mortality
- Lymphoma, Large B-Cell, Diffuse/pathology
- Lymphoma, Large-Cell, Immunoblastic/classification
- Lymphoma, Large-Cell, Immunoblastic/mortality
- Lymphoma, Large-Cell, Immunoblastic/pathology
- Male
- Middle Aged
- Plasma Cells/pathology
- Prognosis
- RNA, Viral/genetics
- Sequence Deletion
- Survival Rate
- Treatment Outcome
Collapse
|
18
|
Parolini O, Kagerbauer B, Simonitsch-Klupp I, Ambros P, Jaeger U, Mann G, Haas OA, Morra M, Gadner H, Terhorst C, Knapp W, Holter W. Analysis of SH2D1A mutations in patients with severe Epstein-Barr virus infections, Burkitt's lymphoma, and Hodgkin's lymphoma. Ann Hematol 2002; 81:441-7. [PMID: 12224001 DOI: 10.1007/s00277-002-0490-3] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2002] [Accepted: 05/22/2002] [Indexed: 11/24/2022]
Abstract
Mutations or deletions in the SH2D1A (src homology 2 domain protein 1A) gene result in a severe immunodeficiency called X-linked lymphoproliferative (XLP) disease. XLP is primarily characterized by a defective immune response against the Epstein-Barr virus (EBV), resulting in an unusually severe and often fatal clinical course following EBV infection. The second major cause of death is the development of B cell lymphomas, both in EBV-infected and EBV-negative patients. To study whether the clinical manifestation of XLP gene defects and/or polymorphisms extends beyond the classically recognized phenotype, we analyzed patients for the presence of SH2D1A gene alterations who presented with fatal or nonfatal, yet unusually severe or chronic EBV infections, and other possibly EBV-associated diseases, such as Hodgkin's lymphomas or nonendemic Burkitt's lymphomas and Burkitt-type leukemias. We identified mutations of the SH2D1A gene only in the majority of patients presenting with fatal mononucleosis or an XLP family history, but not in any of the other patients studied. The only alteration determined was a polymorphism in the 5' region of the SH2D1A gene both in patient groups as well as in controls.
Collapse
Affiliation(s)
- O Parolini
- Institute of Immunology, University of Vienna, Austria.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|